Descrizione del progetto
Aprire la strada a un nuovo dispositivo diagnostico per le nascite premature
Secondo l’Organizzazione Mondiale della Sanità, sono 15 milioni i bambini che nascono prematuramente ogni anno. Un parto si definisce prematuro quando avviene prima del completamento delle 37 settimane di gestazione e le relative complicanze aumentano considerevolmente il rischio di decesso infantile. Pregnolia AG, con sede in Svizzera, intende essere la prima azienda a vendere un dispositivo diagnostico in grado di stabilire il rischio di parto prematuro sulla base della rigidità della cervice uterina, fornendo così una soluzione alle donne che si sottopongono agli esami di routine durante la gravidanza. Il progetto CervixCare, finanziato dall’UE, caratterizzerà scientificamente e tecnologicamente il dispositivo ginecologico misurandone le funzionalità e raccogliendo evidenze cliniche per convalidare il proprio valore.
Obiettivo
Pregnolia was founded in 2016, as a spin-off from the ETH Zurich and aims to be the first company selling a diagnostic device to determine the risk of Premature Birth (PTB) based on the measurements of cervical tissue stiffness to provide a solution that is usable by any woman undergoing routine pregnancy examinations. The goal of CervixCare is to scientifically and technologically characterize the gynaecological device in terms of measuring functions and gather clinical evidence to validate the diagnostic value of the medical device.The uniqueness of the system relies on its novel methodology to detect the risk of PTB, as there is no other commercially available solution based on the cervix stiffness.
The proposed recruitment of an Innovation Associate in CervixCare will have significant impact on the business opportunities of Pregnolia by bringing in lacking expertise for the validation and certification of Pregnolia’s System into a diagnostic medical device. The envisaged grant will help to overcome the recruitment barriers of being a relatively unknown, small start-up enterprise that cannot compete with larger companies due to limited visibility, salary, recruitment budget and (perceived) career opportunities.
CervixCare requires a multi-disciplinary scientist that understands the biomechanics for soft tissue, is able to model/simulate data by performing experiments and is able to use data for complex requirements for clinical validation and regulation of the diagnostic medical device. The main added value of the CervixCare project for the IA is the opportunity to pursue the transition from an academic environment focusing on basic research to a business environment focusing on developing competitive and cutting-edge products. Next to this, the IA will have the opportunity to influence and participate in the early stages of a new and innovative diagnostic device company.
Campo scientifico
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-INNOSUP-2020-02
Meccanismo di finanziamento
CSA-LSP - Coordination and support action Lump sumCoordinatore
8952 Schlieren
Svizzera
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.